Aqilion and Merck partner to develop TAK1 protein inhibitorsTAK1 protein inhibitors

17 Feb 2023
www.pharmaceutical-technology.com
License out/inPROTACs
Aqilion and Merck partner to develop TAK1 protein inhibitors
Preview
Source: Pharmaceutical Technology
The partnership aims to develop TAK1 therapeutics to treat several autoimmune and inflammatory diseases, including neurological diseases. Credit: Josh Riemer / Unsplash.
Aqilion and Merck have entered an exclusive licence and strategic research partnership for the discovery, development and commercialisation of the transforming growth factor-β-activated kinase 1 (TAK1) protein-small molecule inhibitors.
Under the deal, Aqilion will receive $10.6m (€10m) in upfront cash payment from Merck and also eligible for up to $1,015m (€950m) in potential development and commercialisation milestone payments, along with tiered royalties on global net sales.
The partnership combines the experience of Aqilion in the selective TAK1 inhibitors discovery with the drug discovery and development capabilities of Merck.
It will aim to develop advanced TAK1 therapeutics for various inflammatory and autoimmune diseases, including neurological diseases.
Aqilion will handle the design and synthesis of the new small molecule TAK1 inhibitors.
Merck will be responsible for leading the preclinical pharmacology and biology trials.
Aqilion CEO Sarah Fredriksson said: “We are delighted and proud to announce this collaboration with Merck as it validates our business strategy of generating highly innovative discovery projects in combination with pro-active business development and early deal-making.
“We are looking forward to working with Merck as this will speed up the process of bringing novel effective treatments to conditions with high unmet medical needs.”
The company develops new therapeutics to treat diseases that are caused by chronic inflammation and dysfunctional immune reactions, including autoimmune diseases.
Earlier this month, Merck reported $13.83bn worldwide sales, representing a 2% increase in the fourth quarter (Q4) of 2022 from $13.52bn in the previous year’s quarter.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.